177 related articles for article (PubMed ID: 29411195)
1. Design, synthesis, and SAR study of highly potent, selective, irreversible covalent JAK3 inhibitors.
He L; Shao M; Wang T; Lan T; Zhang C; Chen L
Mol Divers; 2018 May; 22(2):343-358. PubMed ID: 29411195
[TBL] [Abstract][Full Text] [Related]
2. Development of Selective Covalent Janus Kinase 3 Inhibitors.
Tan L; Akahane K; McNally R; Reyskens KM; Ficarro SB; Liu S; Herter-Sprie GS; Koyama S; Pattison MJ; Labella K; Johannessen L; Akbay EA; Wong KK; Frank DA; Marto JA; Look TA; Arthur JS; Eck MJ; Gray NS
J Med Chem; 2015 Aug; 58(16):6589-606. PubMed ID: 26258521
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and pharmacological evaluation of 4- or 6-phenyl-pyrimidine derivatives as novel and selective Janus kinase 3 inhibitors.
Shu L; Chen C; Huan X; Huang H; Wang M; Zhang J; Yan Y; Liu J; Zhang T; Zhang D
Eur J Med Chem; 2020 Apr; 191():112148. PubMed ID: 32097841
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design and synthesis of pyrimidine-4,6-diamine derivatives as Janus kinase 3 inhibitors.
Yu RN; Chen CJ; Shu L; Yin Y; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1646-1657. PubMed ID: 30853331
[TBL] [Abstract][Full Text] [Related]
5. Design and Synthesis of a Highly Selective JAK3 Inhibitor for the Treatment of Rheumatoid Arthritis.
He L; Pei H; Lan T; Tang M; Zhang C; Chen L
Arch Pharm (Weinheim); 2017 Nov; 350(11):. PubMed ID: 28944566
[TBL] [Abstract][Full Text] [Related]
6. Discovery of highly potent, selective, covalent inhibitors of JAK3.
Kempson J; Ovalle D; Guo J; Wrobleski ST; Lin S; Spergel SH; Duan JJ; Jiang B; Lu Z; Das J; Yang BV; Hynes J; Wu H; Tokarski J; Sack JS; Khan J; Schieven G; Blatt Y; Chaudhry C; Salter-Cid LM; Fura A; Barrish JC; Carter PH; Pitts WJ
Bioorg Med Chem Lett; 2017 Oct; 27(20):4622-4625. PubMed ID: 28927786
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis.
Yao H; Zhang J; Zheng Q; Zeng X; Huang H; Ling Z; Tang M; Chen Z; Wang W; He L
Arch Pharm (Weinheim); 2024 Jun; 357(6):e2300753. PubMed ID: 38442328
[TBL] [Abstract][Full Text] [Related]
8. Tricyclic covalent inhibitors selectively target Jak3 through an active site thiol.
Goedken ER; Argiriadi MA; Banach DL; Fiamengo BA; Foley SE; Frank KE; George JS; Harris CM; Hobson AD; Ihle DC; Marcotte D; Merta PJ; Michalak ME; Murdock SE; Tomlinson MJ; Voss JW
J Biol Chem; 2015 Feb; 290(8):4573-4589. PubMed ID: 25552479
[TBL] [Abstract][Full Text] [Related]
9. Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis.
Yin Y; Chen CJ; Yu RN; Shu L; Wang ZJ; Zhang TT; Zhang DY
Bioorg Chem; 2020 May; 98():103720. PubMed ID: 32171982
[TBL] [Abstract][Full Text] [Related]
10. Selective JAK3 Inhibitors with a Covalent Reversible Binding Mode Targeting a New Induced Fit Binding Pocket.
Forster M; Chaikuad A; Bauer SM; Holstein J; Robers MB; Corona CR; Gehringer M; Pfaffenrot E; Ghoreschi K; Knapp S; Laufer SA
Cell Chem Biol; 2016 Nov; 23(11):1335-1340. PubMed ID: 27840070
[TBL] [Abstract][Full Text] [Related]
11. Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors.
Casimiro-Garcia A; Trujillo JI; Vajdos F; Juba B; Banker ME; Aulabaugh A; Balbo P; Bauman J; Chrencik J; Coe JW; Czerwinski R; Dowty M; Knafels JD; Kwon S; Leung L; Liang S; Robinson RP; Telliez JB; Unwalla R; Yang X; Thorarensen A
J Med Chem; 2018 Dec; 61(23):10665-10699. PubMed ID: 30423248
[TBL] [Abstract][Full Text] [Related]
12. Structure-based design and synthesis of 1H-pyrazolo[3,4-d]pyrimidin-4-amino derivatives as Janus kinase 3 inhibitors.
Yin Y; Chen CJ; Yu RN; Wang ZJ; Zhang TT; Zhang DY
Bioorg Med Chem; 2018 Sep; 26(17):4774-4786. PubMed ID: 30139575
[TBL] [Abstract][Full Text] [Related]
13. Anilino-monoindolylmaleimides as potent and selective JAK3 inhibitors.
McDonnell ME; Bian H; Wrobel J; Smith GR; Liang S; Ma H; Reitz AB
Bioorg Med Chem Lett; 2014 Feb; 24(4):1116-21. PubMed ID: 24461299
[TBL] [Abstract][Full Text] [Related]
14. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in JAK3 inhibition: Isoform selectivity by covalent cysteine targeting.
Forster M; Gehringer M; Laufer SA
Bioorg Med Chem Lett; 2017 Sep; 27(18):4229-4237. PubMed ID: 28844493
[TBL] [Abstract][Full Text] [Related]
16. Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.
Lynch SM; DeVicente J; Hermann JC; Jaime-Figueroa S; Jin S; Kuglstatter A; Li H; Lovey A; Menke J; Niu L; Patel V; Roy D; Soth M; Steiner S; Tivitmahaisoon P; Vu MD; Yee C
Bioorg Med Chem Lett; 2013 May; 23(9):2793-800. PubMed ID: 23540648
[TBL] [Abstract][Full Text] [Related]
17. Discovery of an Orally Available Janus Kinase 3 Selective Covalent Inhibitor.
Shi L; Zhong Z; Li X; Zhou Y; Pan Z
J Med Chem; 2019 Jan; 62(2):1054-1066. PubMed ID: 30615446
[TBL] [Abstract][Full Text] [Related]
18. Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((2S,5R)-5-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans.
Thorarensen A; Dowty ME; Banker ME; Juba B; Jussif J; Lin T; Vincent F; Czerwinski RM; Casimiro-Garcia A; Unwalla R; Trujillo JI; Liang S; Balbo P; Che Y; Gilbert AM; Brown MF; Hayward M; Montgomery J; Leung L; Yang X; Soucy S; Hegen M; Coe J; Langille J; Vajdos F; Chrencik J; Telliez JB
J Med Chem; 2017 Mar; 60(5):1971-1993. PubMed ID: 28139931
[TBL] [Abstract][Full Text] [Related]
19. Current Status in the Discovery of Covalent Janus Kinase 3 (JAK3) Inhibitors.
Dai J; Yang L; Addison G
Mini Rev Med Chem; 2019; 19(18):1531-1543. PubMed ID: 31288716
[TBL] [Abstract][Full Text] [Related]
20. Development, Optimization, and Structure-Activity Relationships of Covalent-Reversible JAK3 Inhibitors Based on a Tricyclic Imidazo[5,4- d]pyrrolo[2,3- b]pyridine Scaffold.
Forster M; Chaikuad A; Dimitrov T; Döring E; Holstein J; Berger BT; Gehringer M; Ghoreschi K; Müller S; Knapp S; Laufer SA
J Med Chem; 2018 Jun; 61(12):5350-5366. PubMed ID: 29852068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
